OBJECTIVE: To evaluate the efficacy and safety of four commonly used Chinese patent medicines in adjuvant treatment of acute upper respiratory infection in children through network Meta-analysis. METHODS: Four kinds of Chinese patent medicines in the treatment of acute upper respiratory infection were selected

including Fuganlin oral liquid

Xiao’er Chaigui Tuire granules（ oral liquid）

Xiao’er Chiqiao Qingre granules and Xiao’er Shuangqing granules. CNKI

Wanfang Data

VIP

PubMed and Web of Science were retrieved to collect randomized controlled trials of the four kinds of Chinese patent medicines combined with conventional western medicines in the treatment of acute upper respiratory infection in children. The retrieval time was from the establishment of the database to Aug. 16 th

2021. After literature screening

data extraction and quality evaluation

RevMan 5. 3

R 4. 0. 3 and Stata15. 1 software were used for statistical analysis. RESULTS: Totally 26 articles were included.（ 1） The total clinical effective rates of four kinds of Chinese patent medicines in adjuvant treatment of acute upper respiratory infection in children were better than those of conventional western medicines alone

the differences were statistically significant（ P<0. 05）

which were consistent with the results of direct Meta-analysis. According to the grade probability diagram

the total clinical effective rate of Fuganlin oral liquid combined with western medicines was the highest

followed by Xiao’er Shuangqing granules combined with western medicines

Xiao’er Chiqiao Qingre granules combined with western medicines

Xiao’er Chaigui Tuire granules（ oral liquid） combined with western medicines. There was no significant difference in the total clinical effective rates of four kinds of Chinese patent medicines combined with western medicines（ P>0. 05）.（ 2） The incidence of adverse drug reactions of Xiao’er Chiqiao Qingre granules was slightly lower than that of Xiao’er Chaigui Tuire granules（ oral liquid）

with no statistically significant difference. No adverse drug reactions of Fuganlin oral liquid and Xiao’er Shuangqing granules were reported in the included literature. CONCLUSIONS: Four kinds of Chinese patent medicines combined with western medicines in the treatment of acute upper respiratory infection in children can significantly increase the curative efficacy

and the therapeutic efficacy of Fuganlin oral liquid combined with western medicines is significant. However

based on the quality of existing literature and limitations of the study

the conclusions need to be validated by more high-quality clinical studies.